These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 38376947)

  • 21. Early use of oral antiviral drugs and the risk of post COVID-19 syndrome: A systematic review and network meta-analysis.
    Jiang J; Li Y; Jiang Q; Jiang Y; Qin H; Li Y
    J Infect; 2024 Aug; 89(2):106190. PubMed ID: 38834107
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Associations of nirmatrelvir-ritonavir treatment with death and clinical improvement in hospitalized patients with COVID-19 during the Omicron wave in Beijing, China: a multicentre, retrospective cohort study.
    Han X; Li C; Yuan X; Cui J; Han Z; Meng J; Zhao W; Xie F; Wang K; Liu Y; Muo G; Xi N; Zheng M; Wang R; Xiao K; Chen W; Xiong J; Zhao D; Zhang X; Han X; Cheng H; Yu Z; Shi Y; Xie W; Xie L
    Ann Med; 2024 Dec; 56(1):2313062. PubMed ID: 38354691
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Determining and Comparing the Real-World Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in Patients Hospitalized With COVID-19.
    Jang YR; Oh Y; Kim JY
    J Korean Med Sci; 2024 Feb; 39(6):e52. PubMed ID: 38374626
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oral Nirmatrelvir-Ritonavir Use and Clinical Outcomes in Pregnant Patients With Coronavirus Disease 2019 (COVID-19).
    Toure BB; Panakam A; Johns SL; Butler SK; Tuomala RE; Diouf K
    Obstet Gynecol; 2024 Feb; 143(2):273-276. PubMed ID: 37963387
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oral Nirmatrelvir-Ritonavir as Postexposure Prophylaxis for Covid-19.
    Hammond J; Yunis C; Fountaine RJ; Luscan G; Burr AM; Zhang W; Wisemandle W; Soares H; Baniecki ML; Hendrick VM; Kalfov V; Pypstra R; Rusnak JM
    N Engl J Med; 2024 Jul; 391(3):224-234. PubMed ID: 39018532
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nirmatrelvir/Ritonavir Use and Hospitalizations or Death in a Previously Uninfected Nonhospitalized High-Risk Population With COVID-19: A Matched Cohort Study.
    Butt AA; Yan P; Shaikh OS; Talisa VB; Omer SB; Mayr FB
    J Infect Dis; 2024 Jan; 229(1):147-154. PubMed ID: 37711076
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical efficacy of nirmatrelvir plus ritonavir in patients with COVID-19 and preexisting cardiovascular diseases.
    Liu TH; Wu JY; Huang PY; Hsu WH; Chuang MH; Tsai YW; Lai CC; Huang CY
    Expert Rev Anti Infect Ther; 2024; 22(1-3):121-128. PubMed ID: 37965890
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Antiviral Effect of Nirmatrelvir/Ritonavir during COVID-19 Pandemic Real-World Data.
    Petrakis V; Rafailidis P; Trypsianis G; Papazoglou D; Panagopoulos P
    Viruses; 2023 Apr; 15(4):. PubMed ID: 37112956
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real-world effectiveness of nirmatrelvir/ritonavir against COVID-19 hospitalizations and severe COVID-19 in community-dwelling elderly Singaporeans during Omicron BA.2, BA.4/5, and XBB transmission.
    Wee LE; Tay AT; Chiew C; Young BE; Wong B; Lim R; Lee CL; Tan J; Vasoo S; Lye DC; Tan KB
    Clin Microbiol Infect; 2023 Oct; 29(10):1328-1333. PubMed ID: 37331509
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-Effectiveness of Oral Nirmatrelvir/Ritonavir in Patients at High Risk for Progression to Severe COVID-19 in the United States.
    Carlson J; Foos V; Kasle A; Mugwagwa T; Draica F; Lee Wiemken T; Nguyen JL; Cha-Silva A; Migliaccio-Walle K; Dzingina M
    Value Health; 2024 Feb; 27(2):164-172. PubMed ID: 38043712
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness of nirmatrelvir/ritonavir in children and adolescents aged 12-17 years following SARS-CoV-2 Omicron infection: A target trial emulation.
    Wong CKH; Lau KTK; Au ICH; Chan SHS; Lau EHY; Cowling BJ; Leung GM
    Nat Commun; 2024 Jun; 15(1):4917. PubMed ID: 38851796
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge.
    Arbel R; Wolff Sagy Y; Hoshen M; Battat E; Lavie G; Sergienko R; Friger M; Waxman JG; Dagan N; Balicer R; Ben-Shlomo Y; Peretz A; Yaron S; Serby D; Hammerman A; Netzer D
    N Engl J Med; 2022 Sep; 387(9):790-798. PubMed ID: 36001529
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Population-based evaluation of the effectiveness of nirmatrelvir-ritonavir for reducing hospital admissions and mortality from COVID-19.
    Schwartz KL; Wang J; Tadrous M; Langford BJ; Daneman N; Leung V; Gomes T; Friedman L; Daley P; Brown KA
    CMAJ; 2023 Feb; 195(6):E220-E226. PubMed ID: 36781188
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interactions listed in the Paxlovid fact sheet, classified according to risks, pharmacological groups, and consequences.
    Azanza JR; Mensa J; González Del Castillo J; Linares Rufo M; Molero JM; Madero Valle N; Barberán J
    Rev Esp Quimioter; 2022 Aug; 35(4):357-361. PubMed ID: 35822605
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molnupiravir, Nirmatrelvir/Ritonavir, or Sotrovimab for High-Risk COVID-19 Patients Infected by the Omicron Variant: Hospitalization, Mortality, and Time until Negative Swab Test in Real Life.
    Cegolon L; Pol R; Simonetti O; Larese Filon F; Luzzati R
    Pharmaceuticals (Basel); 2023 May; 16(5):. PubMed ID: 37242504
    [No Abstract]   [Full Text] [Related]  

  • 36. [Nirmatrelvir plus ritonavir (Paxlovid) a potent SARS-CoV-2 3CLpro protease inhibitor combination].
    Reina J; Iglesias C
    Rev Esp Quimioter; 2022 Jun; 35(3):236-240. PubMed ID: 35183067
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Delayed treatment with nirmatrelvir/ritonavir could remain effective in patients with Omicron BA2.2 variant of COVID-19.
    Wang W; Wan J; Du W; Song J; Lu Y; Gu S; Feng Y; Wang G; Tao M; Yin J
    Ann Acad Med Singap; 2023 Mar; 52(3):158-160. PubMed ID: 38904494
    [No Abstract]   [Full Text] [Related]  

  • 38. The Impact of Nirmatrelvir-Ritonavir in Reducing Hospitalizations Among High-Risk Patients With SARS-CoV-2 During the Omicron Predominant Era.
    Al-Obaidi MM; Gungor AB; Murugapandian S; Thajudeen B; Mansour I; Wong RC; Tanriover B; Zangeneh TT
    Am J Med; 2023 Jun; 136(6):577-584. PubMed ID: 36898600
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nirmatrelvir/ritonavir or Molnupiravir for treatment of non-hospitalized patients with COVID-19 at risk of disease progression.
    Butt AA; Yan P; Shaikh OS
    PLoS One; 2024; 19(6):e0298254. PubMed ID: 38843201
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Innovative Randomized Phase I Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID-19 Trial of Nirmatrelvir.
    Singh RSP; Toussi SS; Hackman F; Chan PL; Rao R; Allen R; Van Eyck L; Pawlak S; Kadar EP; Clark F; Shi H; Anderson AS; Binks M; Menon S; Nucci G; Bergman A
    Clin Pharmacol Ther; 2022 Jul; 112(1):101-111. PubMed ID: 35388471
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.